These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31246158)

  • 21. Evaluation of the sensitivity and specificity of basal plasma adrenocorticotrophic hormone concentration for diagnosing pituitary pars intermedia dysfunction in horses: A systematic review.
    Tatum RC; McGowan CM; Ireland JL
    Vet J; 2021 Sep; 275():105695. PubMed ID: 34099343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of equine pituitary pars intermedia dysfunction.
    Stewart AJ; Ireland JL; Durham AE; McGowan CM
    Vet J; 2023; 300-302():106036. PubMed ID: 37805159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
    Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
    Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of dynamic testing for pituitary pars intermedia dysfunction diagnosis in donkeys.
    Mejia-Pereira S; Perez-Ecija A; Buchanan BR; Toribio RE; Mendoza FJ
    Equine Vet J; 2019 Jul; 51(4):481-488. PubMed ID: 30362589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strongyle egg shedding and egg reappearance periods in horses with pituitary pars intermedia dysfunction.
    Horner A; Bamford NJ; Stear MJ; Piedrafita D; Jabbar A; Hughes KJ; El-Hage CM; Preston S
    Vet Parasitol; 2024 Jun; 328():110176. PubMed ID: 38603926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
    Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
    Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
    Rendle DI; Doran G; Ireland J; Edwards S
    Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
    Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
    Vet J; 2023; 300-302():106035. PubMed ID: 37802466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
    Miller AB; Murphy BA; Adams AA
    Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial analytic quality assessment and method comparison of an immunoassay for adrenocorticotropic hormone measurement in equine samples.
    Irvine KL; Burt K; Hill AJ; Shaw S; Papasouliotis K
    Vet Clin Pathol; 2016 Mar; 45(1):154-63. PubMed ID: 26756538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circannual variability in adrenocorticotropic hormone responses to administration of thyrotropin-releasing hormone in clinically normal horses in Australia.
    Byrne DP; Secombe CJ; Tan RHH; Perera DI; Watts SP; Wearn JG
    Vet J; 2018 Aug; 238():58-62. PubMed ID: 30103916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circadian and circannual rhythms of cortisol, ACTH, and α-melanocyte-stimulating hormone in healthy horses.
    Cordero M; Brorsen BW; McFarlane D
    Domest Anim Endocrinol; 2012 Nov; 43(4):317-24. PubMed ID: 22717182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
    Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
    Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.
    Horn R; Stewart AJ; Jackson KV; Dryburgh EL; Medina-Torres CE; Bertin FR
    J Vet Intern Med; 2021 Jan; 35(1):560-570. PubMed ID: 33368633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically and temporally specific diagnostic thresholds for plasma ACTH in the horse.
    Durham AE; Clarke BR; Potier JFN; Hammarstrand R; Malone GL
    Equine Vet J; 2021 Mar; 53(2):250-260. PubMed ID: 32470177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses.
    Kam YN; McKenzie K; Coyle M; Bertin FR
    J Vet Intern Med; 2021 Nov; 35(6):2885-2890. PubMed ID: 34642962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of advanced age and pituitary pars intermedia dysfunction on components of the acute phase reaction in horses.
    Zak A; Siwinska N; Elzinga S; Barker VD; Stefaniak T; Schanbacher BJ; Place NJ; Niedzwiedz A; Adams AA
    Domest Anim Endocrinol; 2020 Jul; 72():106476. PubMed ID: 32380311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body phenylalanine kinetics and skeletal muscle protein signaling in horses with pituitary pars intermedia dysfunction.
    Mastro LM; Adams AA; Urschel KL
    Am J Vet Res; 2014 Jul; 75(7):658-67. PubMed ID: 24959733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
    Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
    Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.